Better Biotech Buy: Celgene vs. Gilead Sciences

Big biotech stocks have been on a roll lately, and industry mainstays Celgene (NASDAQ: CELG  ) and Gilead Sciences (NASDAQ: GILD  ) are no exceptions. Each stock has gained more than 50% over the past year as these two companies surge behind older established cash cow drugs while putting their hopes behind ballyhooed new therapies in development and on the market. In the long run, however, which biotech stocks are poised to reward investors the most?

Celgene has a lot going for it. The company's flagship therapy, Revlimid, saw revenue jump more than 13% year over year in its most recent quarter. However, while Revlimid's patent won't expire for some time now, Celgene's reliance on the drug -- Revlimid makes up more than 60% of the company's total sales -- has led to some questioning the stock's long-term future. Gilead, on the other hand, has investors excited behind up-and-coming HIV therapy Stribild and recently approved oral hepatitis C drug Sovaldi, which has exploded onto the scene in its first few months on the market.

Can Sovaldi's promise power Gilead's future, or is Celgene and Revlimid's reliability the best bet for your portfolio? Find out in the video below as Motley Fool contributor Dan Carroll takes you through what makes these two big biotech stocks so appealing -- and which one is the better buy for your financial future.

Can this under-the-radar stock beat both Celgene and Gilead in 2014?
Celgene and Gilead have exceeded all expectations in their run-ups to among the best biotech stocks on the market, but not every health-care pick pans out so well. After all, there's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2864372, ~/Articles/ArticleHandler.aspx, 9/22/2014 10:25:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 hour ago Sponsored by:
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASD 4,527.69 -52.10 -1.14%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/22/2014 3:59 PM
CELG $92.19 Down -1.66 -1.77%
Celgene CAPS Rating: *****
GILD $105.47 Down -0.49 -0.46%
Gilead Sciences CAPS Rating: ****
AMGN $142.18 Down -1.83 -1.27%
Amgen, Inc. CAPS Rating: ****

Advertisement